Market Snapshot
Market Pulse: Crypto teetered at the edge after funding rates across the board slipped negative, igniting short-squeeze speculation while AI collectibles posted eye-popping gains.
Key Movers: Bitcoin bore the brunt of a negative funding signal, per Cointelegraph’s “Negative Bitcoin funding rate may signal pending short-squeeze above $70K,” and AI-memecoin SIREN ripped nearly 100% overnight, according to Ambcrypto.
Macro & Politics: Citriniresearch’s “Global Intelligence Crisis” flags rising geopolitical flashpoints, and Naturalnews’s “The IBT Labs Scandal” underscores how regulatory capture can blindside portfolios.
What’s Next: Keep an eye on Fed and Treasury chatter at the open for potential risk-off whipsaws and momentum-driven breakouts.
Market Commentary
What everyone’s missing is that the FDA’s new proposal for custom rare-disease therapies (Boston Herald’s “FDA proposes new system for approving customized drugs and therapies for rare diseases”) is a hell of a catalyst that could turbocharge small-cap biotechs long before Bitcoin squeezes go live.
It’s absurd to treat AI-memecoin SIREN’s 97% surge and eBay’s Depop acquisition as separate narratives—Ambcrypto’s “AI-memecoin SIREN surges 97% – Assessing if bot-driven demand can lead to…” and MarketBeat’s “Why eBay’s Depop Acquisition Matters More Than the Earnings Beat” both showcase how herd-driven momentum and strategic integration can inflate valuations overnight, and this same psychology is bubbling under multiple markets.
Cut leverage around high-beta plays, rotate capital into biotechs with FDA tailwinds like remibrutinib ahead of Phase data, and stash dry powder to capitalize on any risk-off whipsaws when Treasury spins another yarn.
📈 Breaking Financial News
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
Kraig Biocraft Laboratories (OTCQB:KBLB) is attracting additional attention, as its spider silk technology is featured on the cover of National Geographic…
Optimism capitulates – Is OP’s short squeeze to $0.16 next?
A bounce fueled by short-squeeze mechanics is possible in the short-term, but the long-term trend was firmly bearish.
Why eBay’s Depop Acquisition Matters More Than the Earnings Beat
eBay’s Q4 results show rising GMV, strong ad growth, and a strategic Depop acquisition, signaling a potential turnaround driven by recommerce and younger…
Negative Bitcoin funding rate may signal pending short-squeeze above $70K
Bitcoin’s range consolidation continues, and a negative funding rate and $3.5 billion short liquidity cluster near $70,000 could serve as fuel for higher if market conditions improve.
Global Neuromodulation Devices Market Anticipating Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight
The neuromodulation devices market is expanding swiftly, propelled by the increasing global incidence of chronic conditions such as pain, epilepsy, and depression. This growth is further supported by notable technological innovations that have enhanced device…
Something doesn't add up. Jobs that “existed”… didn't in reality. The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER.
Click here to see where the money is going. Not AI stocks.
🔍 Market Analysis & Insights
FDA proposes new system for approving customized drugs and therapies for rare diseases
The FDA announcement specifically mentions gene editing.
Bitcoin Mirrors Software Stocks More Than Any Other Market — Here’s Why
Bitcoin has increasingly moved in sync with the software and technology sector, and is reshaping its role in global finance. Rather than behaving like a traditional store of value or independent asset class, BTC has shown price patterns closely tied to techno…
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that …
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton’s tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for …
Global Intelligence Crisis
A Thought Exercise in Financial History, from the Future
The Liquidity Engine Powering Crypto's Comeback The post-tariff crypto boom is upon us
Institutional capital is flooding in while most investors remain completely unaware – creating what could be the buying opportunity of a lifetime. Exposed: Crypto's liquidity backbone set for massive gains – get all details for just $3!
💰 Investment Opportunities
Citi Notes Snowflake’s (SNOW) 30% Pull Back to Be an Overreaction
Snowflake Inc. (NYSE:SNOW) is one of theMost Promising Stocks to Invest In Before They Take Off. On February 18, Citi analyst Tyler Radke noted that the…
AI-memecoin SIREN surges 97% – Assessing if bot-driven demand can lead to…
Algorithmic wallets entered early, shifting the structure beneath the rally.
The IBT Labs Scandal: How Monsanto’s Toxic Cover-Up Launched Glyphosate
The Fraudulent Foundation: How IBT Labs Became America’s Toxic Gatekeeper In the early 1970s, a single private laboratory stood as the gatekeeper for the safety of America’s chemical landscape. Industrial Bio-Test Laboratories (IBT), founded in 1953 by Northw…
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients 78% of patients achieved intestinal healin…